CN100591335C - Artificial musk oral disintegration tablet for preventing and fast first aid stenocardia and its preparation method - Google Patents
Artificial musk oral disintegration tablet for preventing and fast first aid stenocardia and its preparation method Download PDFInfo
- Publication number
- CN100591335C CN100591335C CN200510123157A CN200510123157A CN100591335C CN 100591335 C CN100591335 C CN 100591335C CN 200510123157 A CN200510123157 A CN 200510123157A CN 200510123157 A CN200510123157 A CN 200510123157A CN 100591335 C CN100591335 C CN 100591335C
- Authority
- CN
- China
- Prior art keywords
- artificial
- moschus
- disintegration tablet
- mixing
- oral disintegration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
An oral disintegrating tablet of artificial musk for preventing and rescuing angina pectoris is prepared from artificial musk, microcrystalline cellulose (MCC), cross-linked polyvinyl pyrrolidone (PVPP), low-substituted hydroxypropyl cellulose (L-HPC), mannitol, magnesium stearate and sweetening agent through grinding, mixing, sieving and tabletting.
Description
One, technical field
The present invention relates to the Chinese medicine preparation technical field, specifically relate to a kind ofly can prevent angina pectoris, and can save anginal artificial musk oral disintegration tablet and preparation method thereof fast.
Two, background technology
The artificial Moschus has the pharmacological action identical with Moschus, have specifically have one's ideas straightened out, the effect of refreshment, promoting blood circulation to remove obstruction in the collateral, reducing swelling and alleviating pain, cure mainly calentura coma, apoplexy syncope due to accumulation of phlegm, stagnation of QI sudden syncope, attacked by pestiferous factors stupor, amenorrhea, trusted subordinate's sudden pain carbuncle scrofula, arthralgia pain numbness, treat all deficient malignant diseases.Modern study shows that Moschus all has remarkable influence to central nervous system, cardio-cerebrovascular etc.
1. to central nervous system's influence: Moschus is two-way influence to the central nervous system, low dose of excited maincenter, and heavy dose then suppresses maincenter.This two-way function and the traditional Chinese medical science had not only been economized " but also controlling infantile convulsion " with Moschus treatment apoplexy and had been conformed to.
To breathe, the influence of blood circulation: Moschus and muscone all have the effect of excited animal breath, and the animal breath frequency and the degree of depth are increased, and Moschus has excitation to isolated heart, can make the increased blood pressure of rabbit, Canis familiaris L., anesthetized cat.Test with cat papillary muscles, guinea pig tracheal smooth muscle etc., can be observed the effect that Moschus can strengthen catecholamine.
3. to the effect in uterus: Moschus is tangible excitation to the animal isolated uterine with in the body uterus, and the latter is more responsive, and the more nogestational again sensitivity of gestation takes place more slowly but more lasting nogestational effect.So the traditional Chinese medical science is always forbidden medicine to Moschus as gestation.
4. antiinflammatory, antibacterial action: Moschus all has positive effect to early, middle and late three phases of inflammation, especially to morning, mid-term acting on stronger, the 3-methylcyclopentadecanol extract can suppress oozing out of granulation capsule liquid that rat Oleum Tiglii causes, antiinflammatory action has been described, further test finds that this effect is best to exudative inflammation, and is inferior to granulation tissue hyperplasia.To the rat arthritis that is caused by the antigen of mycobacterium injection, its antiinflammation is better than PBZ.The reason that on the traditional medicine Moschus is used for the treatment of swollen ulcer drug may be based on this.The diluent of muscone can suppress escherichia coli and staphylococcus aureus in vitro.
5. antiulcer: directly smear the rat coat of the stomach with dense glacial acetic acid, bring out the chronic experiment ulcer, press the oral Moschus suspension of 200mgkg-1 then.The result shows that Moschus has obvious facilitation to the healing of ulcer surface.The generation of this effect may have relation with its antiinflammatory, granulation promoting, analgesia, hemostatic effect.
6. antitumor action: Moschus is used for the treatment of tumor, the life of prolongation is arranged, dwindle the effect of tumor.
7. immunomodulating: a large amount of research prompting: play an important role in the nerve root pathogenic process of inflammatory reaction behind intervertebral disk hernia, body is to the autoimmune response that regression or outstanding disc tissue produce, and may be to produce inflammation and then cause root pain or one of the reason of cervical spondylosis.Moschus can reduce that IgG content is a kind of immunoregulation effect in the regression cervical intervertebral disk, can alleviate the immunoreation and the inflammatory reaction that cause regression intervertebral disc self.
8. androgen-like action: muscone contains androsterone, effect with androgen sample, ether extract with injection Moschus after the rat castration, can increase the weight of rat prostate and seminal vesicle, the low activity value of the submaxillary gland protease of castration mouse or female mice, be male high activity value owing to giving the Moschus composition, and the G6P-DH value reduces its activity owing to the androgen-like action of Moschus, so the Moschus ether extract has quite the hormone effect like the testosterone sample.
Because Moschus pharmacological action widely, its application clinically is also very extensive, and to the more deep research of Moschus pharmacological action, the potential applicability in clinical practice of Moschus will be more wide also along with in recent years.Modern age, clinical report was oral or treat angina pectoris with artificial ambrosiac mist agent with the artificial Moschus sheet, all obtain good result: make Moschus angina pectoris cream by Moschus, Fructus Gleditsiae Abnormalis, the Radix Angelicae Dahuricae etc., spread on pareordia sore spot and XINYU acupoint respectively, changed once in 24 hours, treatment coronary heart disease, angina pectoris, use the musk injection subcutaneous injection, the treatment vitiligo all has produce effects; Bury or digestive tract tumor such as musk injection treatment hepatocarcinoma and esophagus, stomach, rectum with Moschus, can improve symptom, promote diet; To the paralysis of poliomyelitis, certain curative effect is also arranged.
Three, summary of the invention
1. goal of the invention
The object of the present invention is to provide and a kind ofly can prevent angina pectoris, and can save anginal artificial musk oral disintegration tablet fast, this oral disintegrating tablet formulation has taking convenience, absorbs soon, and the bioavailability height is to characteristics such as the digestive tract mucous membrane irritation are little.
Another object of the present invention provides the preparation method of this oral disintegrating tablet formulation.
2, technical scheme
(1) raw material of artificial musk oral disintegration tablet is formed and weight proportion.
A kind of artificial musk oral disintegration tablet, it is characterized in that it is made by following materials of weight proportions: every consumption is artificial Moschus 0.03～0.1g, microcrystalline Cellulose (MCC) 0.3～1.0g, crospolyvinylpyrrolidone (PVPP) 0.03～0.1g, low-substituted hydroxypropyl cellulose (L-HPC) 0.06～0.2g, mannitol 0.18～0.6g, magnesium stearate 0.006～0.02g, sweeting agent (aspartame or protein sugar) 0.01～0.03g.
(2) preparation method of artificial musk oral disintegration tablet, its preparation process is:
1. take by weighing microcrystalline Cellulose (MCC) 0.3～1.0g, crospolyvinylpyrrolidone (PVPP) 0.03～0.1g, low-substituted hydroxypropyl cellulose (L-HPC) 0.06～0.2g, the equivalent incremental method grinds mixing, crosses 50 mesh sieves, mixing;
2. get mannitol 0.18～0.6g in addition, magnesium stearate 0.006～0.02g, sweeting agent (aspartame or protein sugar) 0.01～0.03g cross 50 mesh sieves, mixing respectively;
3. get artificial Moschus 0.03～0.1g,, cross 50 mesh sieves its porphyrize;
4. with principal agent artificial Moschus and above-mentioned steps 1., 2. adjuvant grinds mixing, crosses 50 mesh sieves, mixing, tabletting makes artificial musk oral disintegration tablet.
(3) application of artificial musk oral disintegration tablet in prevention and quick rescue angina drug.
3, beneficial effect
Artificial musk oral disintegration tablet of the present invention mainly is to utilize its effect to blood vessel and heart etc., thereby reaches the prevention angina pectoris and save anginal purpose fast.
And artificial Moschus and corresponding auxiliary material are made oral disintegrating tablet formulation, its irreplaceable advantage is also arranged.The excellent characteristics of oral disintegrating tablet formulation: can not need water when (1) taking convenience oral cavity disintegration tablet is taken, disintegrate rapidly in the 30s does not have trapping phenomena in esophagus in the oral cavity.This provides great convenience for the patient of the difficult change of child, old people, some psychiatric patient and bed position.(2) absorbing fast, the high oral rapidly disintegrating characteristic of bioavailability the medicine absorption area is increased, and absorb easily, fast, is 125% of commercially available conventional tablet as famotidine oral cavity disintegration tablet bioavailability.(3) after the disintegrate of gastrointestinal mucosal stimulation osculum disintegrating tablet was swallowed, because of the saliva amount is few, drug particles was thin, can be at the stomach uniform distribution, and absorption or embedding gastric mucosa, absorbtivity increases, also can be because of the excessive generation stimulation of the local dose of gastric mucosa.
Old people and infant medication are the major issue that medical worker paid close attention to for a long time always, and along with the development of the aging of the raising of people's living standard, particularly Chinese society, this problem is more and more outstanding.The solution that appears as this problem of oral cavity disintegration tablet provides great convenience.In addition, this dosage form can adopt common film-making technology, reduced the cost of tablet to a great extent, so fast disintegrating oral tablet has good market prospect.
The development of oral cavity disintegration tablet is that new approach has been opened up in emergent treatment, also provide a new method simultaneously for the oral absorption that solves insoluble drug, be applicable to old people and child's oral medication, especially for gulping down the cancer chemotherapy patient that water promptly vomits, have more suitable use advantage, thereby found a kind of way of solution for the quality of life of improving patient; Medical treatment for special circumstances such as the geologist of field work drinking-water inconvenience and desert area people provides convenience in addition, and new thinking also is provided for disintegration of tablet degree before solving is bad.Wideling popularize of oral cavity disintegration tablet, except that the reform that will promote preparation tablets, will cause that also pharmaceutical technology, adjuvant are made and the huge revolution of clinical application, in the innovation of route of administration, has epoch making significance, will create huge economic and social benefit, and artificial Moschus's oral cavity disintegration tablet also has irreplaceable effect in treatment angina pectoris emergency case.
Four, the specific embodiment
The raw material of embodiment 1 artificial musk oral disintegration tablet is formed and weight proportion
A kind of artificial Moschus's oral cavity disintegration tablet, it is characterized in that it is to be made by following materials of weight proportions: every consumption is artificial Moschus 0.06g, microcrystalline Cellulose (MCC) 0.6g, crospolyvinylpyrrolidone (PVPP) 0.6g, low-substituted hydroxypropyl cellulose (L-HPC) 0.1g, mannitol 0.18～0.6g, magnesium stearate 0.01g, aspartame 0.02g.
The preparation method of 2 one kinds of artificial musk oral disintegration tablets of embodiment, its preparation process is:
1. take by weighing microcrystalline Cellulose (MCC) 0.6g, crospolyvinylpyrrolidone (PVPP) 0.6g, low-substituted hydroxypropyl cellulose (L-HPC) 0.1g, the equivalent incremental method grinds mixing, crosses 50 mesh sieves, mixing;
2. get mannitol 0.18～0.6g in addition, magnesium stearate 0.01g, aspartame 0.02g cross 50 mesh sieves, mixing respectively;
3. get artificial Moschus 0.06g,, cross 50 mesh sieves its porphyrize;
4. with principal agent artificial Moschus and above-mentioned steps 1., 2. adjuvant grinds mixing, crosses 50 mesh sieves, mixing, tabletting makes artificial musk oral disintegration tablet.
Claims (3)
1, a kind of artificial musk oral disintegration tablet, it is characterized in that it is to be made by following materials of weight proportions: every consumption is artificial Moschus 0.06g, microcrystalline Cellulose 0.6g, crospolyvinylpyrrolidone 0.6g, low-substituted hydroxypropyl cellulose 0.1g, mannitol 0.18～0.6g, magnesium stearate 0.01g, sweeting agent 0.02g.
2, a kind of method for preparing claim 1 artificial musk oral disintegration tablet, its preparation process is:
(1) take by weighing microcrystalline Cellulose 0.6g, crospolyvinylpyrrolidone 0.6g, low-substituted hydroxypropyl cellulose 0.1g grinds mixing, crosses 50 mesh sieves, and mixing is standby;
(2) get mannitol 0.18～0.6g in addition, magnesium stearate 0.01g, sweeting agent 0.02g cross 50 mesh sieves respectively, and mixing is standby;
(3) get artificial Moschus 0.06g,, cross 50 mesh sieves its porphyrize;
(4) adjuvant with principal agent artificial Moschus and above-mentioned (1), (2) step grinds mixing, crosses 50 mesh sieves, mixing, and tabletting makes artificial musk oral disintegration tablet.
3, the described artificial musk oral disintegration tablet of claim 1 is in prevention with save application in the angina drug fast.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510123157A CN100591335C (en) | 2005-12-19 | 2005-12-19 | Artificial musk oral disintegration tablet for preventing and fast first aid stenocardia and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510123157A CN100591335C (en) | 2005-12-19 | 2005-12-19 | Artificial musk oral disintegration tablet for preventing and fast first aid stenocardia and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1823844A CN1823844A (en) | 2006-08-30 |
| CN100591335C true CN100591335C (en) | 2010-02-24 |
Family
ID=36934784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200510123157A Expired - Fee Related CN100591335C (en) | 2005-12-19 | 2005-12-19 | Artificial musk oral disintegration tablet for preventing and fast first aid stenocardia and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100591335C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897692B (en) * | 2009-05-27 | 2011-07-06 | 澳门科技大学 | Artificial muskiness and isosorbide mononitrate composite orally disintegrating tablet and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1698873A (en) * | 2005-05-27 | 2005-11-23 | 北京科信必成医药科技发展有限公司 | Orally disintegrating tablet of 'Tianli Bolus' for treating heart disease and its preparation process |
-
2005
- 2005-12-19 CN CN200510123157A patent/CN100591335C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1698873A (en) * | 2005-05-27 | 2005-11-23 | 北京科信必成医药科技发展有限公司 | Orally disintegrating tablet of 'Tianli Bolus' for treating heart disease and its preparation process |
Non-Patent Citations (2)
| Title |
|---|
| 中药分散片研究进展. 蔡治纲等.中成药，第26卷第9期. 2004 |
| 中药分散片研究进展. 蔡治纲等.中成药，第26卷第9期. 2004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1823844A (en) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101744833B (en) | Medicinal composition for treating bacterial vaginitis | |
| CN101698101B (en) | Medicine composite for treating vaginitis | |
| CN103845348B (en) | 20 (R)-ginsenoside Rg3s application in preparation dysmenorrhea medicine | |
| CN101292969B (en) | Application of butyric acid (butanoic acid) in preparing medicaments for treating anorectal diseases | |
| WO2014059880A1 (en) | Method for preparation of pomegranate-peel polyphenol gel used to treat gynecological inflammation | |
| CN1785367A (en) | Medicine for trenting flooding and spotting, haematemesis and homafecia | |
| CN116350593A (en) | Composite active freeze-dried powder, composite active freeze-dried powder orally disintegrating tablet, and preparation methods and application thereof | |
| CN101461788A (en) | Phloroglucine orally disintegrating tablet and preparation method thereof | |
| CN100591335C (en) | Artificial musk oral disintegration tablet for preventing and fast first aid stenocardia and its preparation method | |
| CN102526640B (en) | Pantoprazole sodium medicine compound and preparation technology thereof | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN101347477A (en) | Medicament composition for treating rheumatoid arthritis | |
| CN100450528C (en) | Funing gel prepn. and its prepn. method | |
| CN110151786A (en) | Application and the drug of the nano carbon particle in the drug of preparation treatment canker sore | |
| CN100342875C (en) | Chinese medicinal capsule for treating piles and its preparing process | |
| TW202126320A (en) | Anisomeles indica bioactive fractions TSYI-813 for treatment or improvement efficacies of stomach ulcer, and compound, preparation method and purpose thereof do not only reduce areas of stomach ulcer but also decrease occurrence of stomach inflammation | |
| CN113397161A (en) | Health food of stomach-changing membrane paste | |
| CN102058734A (en) | Chinese medicinal adhesive tablets for treating oral mucosa ulcer | |
| CN111358833A (en) | Prunella vulgaris extract and application thereof in preparation of medicines for treating thyroid diseases | |
| CN113577090B (en) | Application of arctiin in preparation of prostatic hyperplasia medicine | |
| CN1739672A (en) | Pile treating Chinese medicine prepn and its production process | |
| CN100484541C (en) | Midicinal composition for treating hemorrhoids and preparation method thereof | |
| CN101919799B (en) | Novel sustained-release transdermal medicament delivery system | |
| CN114159435B (en) | Application of Fuziling in preparing medicine for treating arthritis | |
| CN104013630A (en) | Compound bazedoxifene acetate estrogen composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100224 Termination date: 20121219 |